In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on Galapagos NV (GLPG), with a price target of $130. The company’s shares opened today at $113.47.
Merle wrote:
“Our Galapagos thesis: We think that 2019 is the year filgotinib will differentiate itself among the JAKs. We reiterate our Overweight and price target of $130. We expect key Phase 3 data from filgotinib in studies called FINCH 1 and 3 in 1Q19. We think that these data may reveal that filgotinib has an attractive risk/benefit profile among the JAK inhibitors. Section may be found on pages 4 – 5.We value Galapagos shares on a probability-adjusted DCF.”
According to TipRanks.com, Merle has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.9% and a 19.4% success rate. Merle covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aerpio Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Galapagos NV has an analyst consensus of Strong Buy, with a price target consensus of $139.75, representing a 23.2% upside. In a report issued on April 29, H.C. Wainwright also maintained a Buy rating on the stock with a $150 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $125.48 and a one-year low of $85. Currently, Galapagos NV has an average volume of 122K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
